Tau inhibition (TauRx Therapeutics product page, hydromethylthionine mesylate) (2026)

Other · TauRx Therapeutics Management Limited · November 21, 2026

TauRx's own medical-professional page describes its investigational product as hydromethylthionine mesylate (HMTM), a tau aggregation inhibitor, and states that the company holds composition-of-matter and use patents on it. The page does not mention methylene blue or explain the change of form.

We have “composition of matter” patents and “use” patents covering the application of our TAIs for the treatment and prevention of Alzheimer’s and frontotemporal dementia (FTD).

TauRx's own medical-professional page describes its investigational product as hydromethylthionine mesylate (HMTM), a tau aggregation inhibitor, and states that the company holds composition-of-matter and use patents on it. The page does not mention methylene blue or explain the change of form. C9 , taurx.com, 'Tau inhibition' page, accessed 2026-11-21 (access date, page undated); site footer reads '©2026 TauRx Therapeutics Management Limited'. Route: direct fetch. The site has no public statement contrasting HMTM with generic methylene blue: the FAQ, company history and product pages were fetched and contain no occurrence of 'methylene blue' (checked programmatically). The rationale for the new form is stated in the patents and in the Lancet paper, not on the website. Study type: other.